The information submitted by prescription drug manufacturers to Oregon’s Drug Price Transparency Program can be explored below. This page is updated every day.
To begin, we suggest selecting one of the options from the Filing Types dropdown, then selecting a particular drug. Descriptions of these options can be found at the bottom of the page.
The Prescription Drug Price Transparency Act requires prescription drug manufacturers to report new specialty prescription drugs, to submit annual reports on any drugs that had large price increases over the past year, and to report planned large price increases. The program also accepts reports from consumers about cost increases they experience for the prescriptions they receive.
This page contains all of the publicly available content in all of these reports received by the Oregon Drug Price Transparency Program. Information claimed by a manufacturer to be trade secret in a report, other information response, or correspondence will not be posted until a final determination has been made by the department or the director. Any information claimed to be a trade secret determined by the department to be exempt from disclosure will not be directly posted publicly, but will be generally described. An explanation for the determination from the department will be included nearby.
There are four main reports types accessible using the Filing Types dropdown:
New Spec. Drug:The Prescription Drug Price Transparency Act requires prescription drug manufacturers to report on new prescription drugs with a price of $670 (the Medicare Part D specialty drug cost threshold) or more. Reports must be submitted to the department within 30 days of the market entry date of a prescription drug meeting the reporting threshold.
Annual Increase:The Prescription Drug Price Transparency Act requires prescription drug manufacturers to report each year on prescription drugs that had a net yearly price increase of 10% or more and had a price of $100 or more for a one month supply (or for a course of treatment lasting less than one month) during the previous year. Reports are required to be submitted to the department on March 15th of each year.
Price Increase:Oregon House Bill 2658 (2019 Regular Session) requires prescription drug manufacturers to report each year on certain planned price increases. For a brand-name drug, a report is required if it will have a cumulative price increase of 10% or more within a 12-month period or if the price will increase by $10,000 or more. For a generic drug, a report is required if it will have a cumulative price increase of 25% or more within a 12-month period or if the price will increase by $300 or more. The report must be submitted 60 days before the price increase will take effect.
Consumer Notification: Anyone from the public can submit a report to the program if they experience an increase in the cost of their prescriptions.
For more information, see the
Drug Price Transparency Program’s annual reports submitted to the Oregon state legislature.
For information on a specific drug, visit the following pages:
For general information on prescription drugs, visit the following pages: